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The Ras Association Domain Family 1A (RASSF1A)
gene is one of the most frequently silenced genes in
human cancer. RASSF1A has been shown to interact
with the proapoptotic kinase MST1. Recent work in
Drosophila has led to the discovery of a new tumor-
suppressor pathway involving the Drosophila MST1
and MST2 ortholog, Hippo, as well as the Lats/Warts
serine/threonine kinase and a protein named Salvador
(Sav). Little is known about this pathway in mamma-
lian cells. We report that complexes consisting of
RASSF1A, MST2, WW45 (the human ortholog of Sav),
and LATS1 exist in human cells. MST2 enhances the
RASSF1A-WW45 interaction, which requires the C-ter-
minal SARAHdomain of both proteins. Components of
this complex are localized at centrosomes and spindle
poles from interphase to telophase and at themidbody
during cytokinesis. Both RASSF1A andWW45 activate
MST2 by promoting MST2 autophosphorylation
and LATS1 phosphorylation. Mitosis is delayed in
Rassf1a2/2 mouse embryo fibroblasts and frequently
results in cytokinesis failure, similar to what has
been observed for LATS1-deficient cells. RASSF1A,
MST2, or WW45 can rescue this defect. The complex
of RASSF1A, MST2, WW45, and LATS1 consists of
several tumor suppressors, is conserved in mam-
malian cells, and appears to be involved in controlling
mitotic exit.
Results and Discussion
RASSF1A is one of the most frequently silenced genes in
human cancer [1, 2], and Rassf1a-targeted mice are
prone to spontaneous and induced tumorigenesis [3].
RASSF1A interacts with the proapoptotic kinase MST1
[4]. Recent work in Drosophila has led to the identifica-
tion of a new tumor-suppressor pathway involving the
Drosophila MST1 and MST2 ortholog, Hippo, as well
as the Lats/Warts serine/threonine kinase and a protein
named Salvador (Sav) [5–10]. Interestingly, RASSF1A,
*Correspondence: gpfeifer@coh.orgMST1, MST2, and Sav all contain a conserved C-termi-
nal domain, which has been referred to as the SARAH
(Salvador, RASSF1, Hippo) domain [11]. This domain is
required for the interaction of RASSF1A with MST1 [4];
it may also be the module for interaction of the other
proteins of the putative complex and possibly form a tri-
merization motif [11]. The identification of a Drosophila
tumor-suppressor pathway involving Hippo/MST,
Salvador/WW45, and LATS kinase suggests the possi-
bility that a similar pathway exists in mammalian cells
and that this pathway includes the RASSF1A tumor sup-
pressor. However, the existence of such a complex has
not yet been demonstrated.
RASSF1A Associates with WW45 and MST2
Mammalian MST1 kinase has been reported to asso-
ciate with RASSF1A [4, 12], and MST2 was shown to in-
teract with WW45 in vitro and after coexpression [13].
We first asked whether there is an interaction between
human RASSF1A and WW45. Expression constructs of
the two proteins were cotransfected into COS7 cells.
HA-WW45 could be coprecipitated with GST-RASSF1A
(Figure 1A). A strong interaction between RASSF1A
and MST2 was also observed (Figure 1B).
To investigate the effect of MST2 on the interaction
between RASSF1A and WW45, we transfected different
amounts of Flag-MST2 into COS7 cells together with
GST-RASSF1A and HA-WW45. The interaction between
GST-RASSF1A and HA-WW45 was increased by MST2
coexpression (Figure 1B). We next tried to determine
whether the C-terminal SARAH domains are required
and sufficient for the interaction between RASSF1A
and WW45. Different HA- and GST-tagged deletion con-
structs of WW45 were made and cotransfected with full-
length GST- or Flag-tagged RASSF1A. The data suggest
that WW45’s C terminus (amino acids 199–383) is neces-
sary for binding to RASSF1A, whereas the N terminus
(amino acids 1–267 and 1–320) is not. The C-terminal
SARAH domain of WW45 (amino acids 321–383) was
sufficient for binding to RASSF1A (see Figure S1 in the
Supplemental Data available online). Next, we mapped
the interaction domain(s) on RASSF1A with different
RASSF1A deletion constructs (Figure S2). Surprisingly,
a putative binding region appeared to be within amino
acids 167–193 of RASSF1A because RASSF1A 1–193
could bind to WW45. whereas RASSF1A 1–167 could
not. However, a construct with an internal deletion of
this region could still bind to WW45. When the RA
domain (amino acids 194–288) was present, such as in
construct RASSF1A 1–288 or 120–288, the interaction
of RASSF1A with WW45 was strongly reduced. Our ex-
planation is that the RA domain may inhibit binding be-
tween RASSF1A 1–193 and WW45 unless the SARAH
domain is also present. Importantly, the SARAH domain
of RASSF1A alone was sufficient to bind to WW45
(Figure S2). We interpret this to mean that there are
two binding sites for WW45 on RASSF1A and that the
SARAH domain is the dominant one.
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(A) Interaction of RASSF1A and WW45. A construct that expresses GST or GST-RASSF1A was cotransfected with HA-tagged WW45 into COS7
cells. After 48 hr, cells were lysed, and lysates were precipitated with a glutathione affinity matrix. The precipitates and lysates were subjected to
10% SDS-PAGE, and western blots were done with HA or GST antibodies.
(B) Effect of MST2 on the interaction between RASSF1A and WW45. GST-RASSF1A (4 mg), HA-WW45 (4 mg), and different amounts (0.4, 0.8, and
2 mg) of Flag-MST2 were transfected into COS7 cells. After 48 hr, cells were lysed, and lysates were adsorbed onto glutathione affinity gels
followed by the indicated western blots.
(C) Interactions of endogenous RASSF1A, MST2, WW45, and LATS1. HeLa cell lysates were incubated with either normal control IgG or the
indicated antibodies against MST2, RASSF1A, or WW45. Precipitated proteins and cell lysates were subjected to 8% SDS-PAGE followed by
western blotting with MST2, WW45, RASSF1A, or LATS1 antibodies.RASSF1A, MST2, WW45, and LATS1 Form
Complexes In Vivo
In Drosophila, the homologs of MST1, MST2, WW45,
LATS1, and LATS2 form a complex and participate in
a novel tumor-suppressor pathway [5–10]. Therefore,
we examined whether a similar complex exists in mam-
malian cells. First, we developed antibodies against
RASSF1A and human WW45 (Figure S2) suitable for im-
munoprecipitation (Figure 1C). Different coimmunopre-
cipitations of the endogenous proteins were performed
in HeLa cells. RASSF1A, WW45, and LATS1 all can be
co-immunoprecipitated with MST2 antibody. RASSF1A,
MST2, and LATS1 were associated with immunopre-
cipitated WW45. Moreover, when RASSF1A antibody
was used for immunoprecipitation, MST2, WW45, and
LATS1 were all present in the precipitated endogenous
protein complexes (Figure 1C). From these results, we
conclude that endogenous protein complexes including
RASSF1A, WW45, MST2, and LATS1 exist in mammalian
cells.
Effect of RASSF1A on MST2 Activation
and LATS1 Phosphorylation
Although recombinant RASSF1A appears to inhibit
MST1 and MST2 kinase activity in vitro, the effect of
RASSF1A on MST1 and MST2 activity in transfected
cells may involve either stimulation or inhibition [12,
14]. In order to further investigate this issue, we cotrans-
fected RASSF1A with MST2 in COS7 cells to determine
whether RASSF1A can promote the activation of
MST2. A phosphospecific MST antibody that recog-
nizes T180-phosphorylated MST2 was used [15].Autophosphorylation of MST2 on threonine 180 was in-
creased by RASSF1A cotransfection (Figure 2A). Be-
cause MST2 T180 is a critical residue for kinase activity
[15], it was thus demonstrated that RASSF1A enhances
MST2 activation. Transfection of WW45 alone (in the
absence of RASSF1A) also activated MST2, but to a
lesser extent than RASSF1A alone or a combination of
RASSF1A and WW45 (Figure 2A). We then assessed
MST2 activation in response to staurosporine treatment
in wild-type and Rassf1a-knockout mouse embryo
fibroblasts (MEFs) by using the P-MST antibody. Stauro-
sporine is one of only a few agents able to activate en-
dogenous MST1 and MST2 [15]. Although staurosporine
efficiently activated MST1 and MST2, no difference in
the absence of Rassf1a was observed (data not shown).
Likewise, Rassf1a-deficient MEFs were not more or less
sensitive than wild-type MEFs to DNA-damaging agents
and microtubule-targeting drugs and did not display
significant differences in apoptosis induction by these
agents (S.T. and G.P.P., unpublished data).
It has been reported that MST2 phosphorylates
LATS1 [13]. We considered that—if RASSF1A activates
MST2—it could also promote LATS1 phosphorylation.
Next, GST-RASSF1A was cotransfected with HA-
LATS1 and Flag-MST2. We performed IP kinase assays
to test whether RASSF1A, dependent on MST2, can en-
hance LATS1 phosphorylation. Transfection of active
Flag-MST2 led to MST2 autophosphorylation (Fig-
ure 2B). MST2 could phosphorylate LATS1, as well as
the kinase-dead form of LATS1 (Figure 2B, lanes 1, 2,
5, 6, 9, 10, 13, and 14). Kinase-dead MST2 served as
a control showing that phosphorylation of LATS1 was
Current Biology
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(A) Effect of RASSF1A on MST2 phosphorylation. Flag-MST2 was cotransfected with plasmids expressing GST, GST-RASSF1A, HA-tag, or
HA-WW45 into COS7 cells. After 48 hr, cells were lysed and precipitated with anti-Flag affinity gel. The precipitates were examined by anti-P-
MST (recognizing MST2-T180P) blot. Expression of Flag-MST2, HA-WW45, and GST-RASSF1A was determined by anti-Flag, anti-HA, and
anti-GST blots. The fragment near 36 kDa on the anti-Flag blots is a caspase-derived cleavage fragment of MST2. Its phosphorylated form
was detectable only after longer exposure of the top gel panel. An asterisk denotes a nonspecific band.
(B) Effect of RASSF1A on MST2 activation and LATS1 phosphorylation. 293T cells were cotransfected with HA-LATS1 wild-type or HA-LATS1
kinase-dead; Flag-MST2 wild-type or Flag-MST2 kinase-dead; and GST-RASSF1A and/or Flag-WW45. Note that the kinase-dead LATS1 con-
struct contains two consecutive HA tags, leading to an enhanced signal. Forty-eight hours after transfection, cells were lysed, and each precip-
itation was performed with HA antibody and protein A/G agarose beads. Precipitates were subject to an in vitro kinase assay as described in the
Supplemental Experimental Procedures. Samples were separated by 8% SDS-PAGE followed by autoradiography. The indicated blots were per-
formed so that the expression levels of the proteins could be determined.
(C) Effect of SARAH-deleted RASSF1A and WW45 constructs on MST2 activation and LATS1 phosphorylation. 293T cells were cotransfected
with an HA-LATS1 wild-type construct, Flag-MST2 wild-type or Flag-MST2 kinase-dead plus GST-RASSF1A and/or Flag-WW45, full-length
or SARAH-domain-deleted constructs. Forty-eight hours after transfection, cells were lysed, and each precipitation was performed with HA
antibody and protein A/G agarose beads. Precipitates were subject to an in vitro kinase assay. The indicated blots were performed so that
the expression levels of the proteins could be determined.due to MST2 activity. This confirmed that the two pro-
teins are associated with each other functionally.
MST2 could be coprecipitated in a stable complex
with LATS1 only in the presence of SARAH-domain-con-
taining RASSF1A and/or WW45 (Figure 2C; lanes 2, 4,
and 6); RASSF1A and WW45 combined had the stron-
gest effect. Substantially increased LATS1 phosphory-
lation was observed when RASSF1A was cotransfected
(Figure 2B, compare lanes 5, 6, 13, and 14 with lanes 1
and 2). WW45 alone also enhanced MST2 activity
(Figure 2B, lanes 9 and 10), but RASSF1A and WW45
combined had an additional effect (Figure 2B, lanes 13
and 14; Figure 2C, lane 6). The data indicate that
RASSF1A and WW45 promote LATS1 phosphorylation
by recruiting MST2 into the complex. Because no spe-
cific substrate of LATS1 is known, we could not directly
test whether LATS1 kinase activity is increased by
MST2. We next determined the role of the SARAH do-
mains in MST2 activation by RASSF1A and WW45. As
shown in Figure 2C, RASSF1A and WW45 with a deleted
SARAH domain were incapable of MST2 activation.
RASSF1A, MST2, WW45, and LATS1 Localize
to the Centrosomes and Midbody
Human LATS1 localizes at centrosomes and the spindle
apparatus in mitotic cells [16]. Because RASSF1A,WW45, MST2, and LATS1 were associated with each
other (Figure 1), we investigated their subcellular locali-
zation patterns. All four proteins (RASSF1A, WW45,
MST2, and LATS1) colocalized with g-tubulin bright
spots in interphase and mitotic cells (Figure 3), support-
ing the notion that the four proteins form a centrosomal
complex. Anaphase localization of the four proteins is
shown in Figure S3. Colocalization experiments were
possible between MST2 (goat antibody) and the other
three proteins (rabbit antibodies) and are shown in
Figure S4. Interestingly, these proteins were localized
at the midbody or the contractile ring during cytokinesis,
which indicates that the complex may be important for
the completion of mitosis. Whereas MST2 and RASSF1A
were consistently observed at the midbody in HeLa
cells, WW45 and LATS1 were localized at the contractile
ring in most cells in late mitosis. However, we also ob-
served anti-RASSF1A staining at both the contractile
ring and midbody in human fibroblasts (data not shown).
Mitotic Defects in Rassf1a-Knockout Cells
LATS1 has been described as a kinase involved in the
mitotic-exit network [17]. Given its cellular localization
(Figure 3) and its effect on LATS1 phosphorylation
(Figure 2), we considered the possibility that RASSF1A
may also be involved in mitotic progression. Using
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703Figure 3. RASSF1A, MST2, WW45, and LATS1 Localize to the Centrosome and Mitotic Apparatus
HeLa cells were grown on coverslips in six-well plates, fixed, and stained with specific antibodies. Cells in interphase (top rows), metaphase
(middle rows), and cytokinesis (bottom rows) are shown.
(A) Purified rabbit anti-RASSF1A and mouse anti-g-tubulin were used for immunostaining.
(B) Rabbit anti-WW45 and mouse anti-g-tubulin were used for coimmunostaining.
(C) Goat anti-MST2 was used for costaining with mouse anti-g-tubulin.
(D) Cells were costained with rabbit anti-LATS1 and mouse anti-g-tubulin.time-lapse video microscopy, we monitored wild-type
MEFs and Rassf1a2/2 MEFs during mitotic cell division
(Figure 4; see also supplemental movies). We observed
that Rassf1a2/2 MEFs required a significantly extended
time period to traverse mitosis (Figure 4). A substantially
increased fraction (40%) of Rassf1a2/2MEFs compared
to wild-type MEFs (17%) did not complete mitosis as
a result of cytokinesis failure (Figure 4). Binucleated
cells formed in most cases. By scoring >2000 cells
of each genotype at passage 3, we found that 17% of
Rassf1a2/2 MEFs (362 of 2134) but only 12.9% of
Rassf1a+/+ MEFs (317 of 2463) had two or more nuclei
(p < 0.001, Chi square test) indicating that multinucle-
ated cells arise in Rassf1a2/2MEFs as a result of defects
in mitosis. Microscopy data obtained by DAPI and
anti-tubulin staining and the counting of all mitotic cells
indicated a mitotic index of 1.22% (41 of 3363 cells) for
wild-type MEFs and 2.27% (27 of 1192 cells) for
Rassf1a2/2MEFs (p < 0.025, Chi square test) consistent
with a defect in mitosis.
The mitotic defect of Rassf1a2/2 cells could be com-
plemented, at least partially, with a lentiviral vector ex-
pressing GFP-RASSF1A, which reduced the number offailed mitoses and accelerated mitotic progression
(Figure 4E). Importantly, GFP-WW45 complemented
the defect almost equally well as RASSF1A, and MST2
also promoted mitotic progression in Rassf1a2/2 cells
relative to the GFP-only control. A construct containing
LATS1 did not express efficiently and could not be
tested. The data suggest that the mitotic defect in
Rassf1a2/2 cells can be complemented by components
of the mammalian Hippo pathway.
The Mammalian Hippo Pathway
This is the first demonstration that the components of
the Hippo pathway interact with each other in mamma-
lian cells. Although we confirmed the existence of
RASSF1A, MST2, WW45, LATS1 complexes, we cannot
exclude the possibility that more than one complex ex-
ists. For example, one could hypothesize that there is
a specific complex involved in apoptosis and that a dif-
ferent complex participates in mitotic exit. The situation
is complicated by the fact that LATS1 also has been
shown to induce apoptosis [18, 19] and by the fact that
multiple family members exist (RASSF1 through
RASSF6, MST1 and MST2, LATS1 and LATS2).
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Wild-type and Rassf1a2/2 MEFs were grown at passage 3 and were observed by time-lapse video microscopy.
(A) Mitosis in a Rassf1a+/+ cell.
(B) Mitosis in a Rassf1a2/2 cell. The white arrows point to the mitotic cells.
(C) Evaluation of the length of mitosis in a total of 112 Rassf1a+/+ cells (blue) and 130 Rassf1a2/2 cells (purple) derived from three independent
embryos for each genotype (error bars, 6 standard deviation).
(D) Diagram showing the outcome of mitosis in wild-type and Rassf1a2/2 cells as determined by video microscopy.
(E) Complementation of the mitotic defect in Rassf1a2/2MEFs by lentiviral vectors expressing GFP-RASSF1A, GFP-WW45, or GFP-MST2. Video
microscopy of the transduced cells was used for monitoring mitotic progression (the total number of cells recorded is shown in parentheses).Mitosis was delayed and frequently resulted in cytoki-
nesis failure in Rassf1a-KO cells (Figure 4). A similar
phenotype has been observed in cells from Lats1-
knockout mice or by RNA-mediated interference tar-
geted against LATS1 [20, 21, 17]. Our data suggest
that LATS1 is a downstream target of RASSF1A,
WW45, and MST2, and inactivation of RASSF1A and
LATS1 produce similar defects in mitotic progression.
Cytokinesis failure can lead to the emergence of tetra-
ploid cells, which are thought to be intermediates on
a path leading to aneuploidy [22]. Lats1- and Rassf1-
knockout mice are prone to tumors [3, 23]. Human
WW45 (Salvador) is deleted in several cancer cell lines
[6]. LATS1 and LATS2 are downregulated by promoter
methylation in about 50% of human breast cancers
[24]. However, RASSF1A is probably the most com-
monly incapacitated component of this emerging
tumor-suppressor pathway [2].
A tentative ortholog of the RASSF family of proteins
can be identified in Drosophila (DmCG4656). In the
C-terminal part (amino acids 190–340), RASSF1A is
28% identical and 45% similar to DmCG4656. However,
this Drosophila gene product is more closely related to
human RASSF2 and RASSF4. Recently, it has been
shown that Drosophila Rassf inhibits the Hippo pathway[25], raising the important question of whether and how
all six mammalian RASSF family members impinge on
this pathway separately and in combination. The path-
ways are likely to be at least partially different in flies
and humans. For example, mitotic defects have not
been reported for fly cells with mutations in hippo, sav,
or lats. The function of the mammalian complex in mi-
totic exit is similar to the function of some of these pro-
teins in yeast, where Cdc15 (the Mst ortholog) activates
Dbf2 (the Lats ortholog) in the mitotic-exit network [26].
However, there are no recognizable RASSF or WW45
orthologs in S. cerevisiae.
In summary, we demonstrated that RASSF1A is
a component of a tumor-suppressor network similar to
one described in Drosophila, which includes the mam-
malian homologs MST2, WW45, and LATS1. Defects in
this pathway may lead to abnormal mitosis and failure
to induce apoptosis. Further investigations are needed
for dissecting the precise regulation of this complex in
cell-cycle progression, apoptosis, and tumorigenesis.
Supplemental Data
Experimental Procedures, five figures, and six supplemental movies
are available with this article online at http://www.current-biology.
com/cgi/content/full/17/8/700/DC1/.
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